The PDUFA date of February 12, 2027, is the primary catalyst — traders should position for binary approval risk/reward. The strong qAF data and Priority Review status increase approval probability, but the stock may have already partially priced this in given the $7B market cap. Watch for interim analysis from the PHOENIX GA trial and the September Commercial Day for additional catalysts. The widening net loss is expected for a pre-commercial biotech and is not a concern given the $780M cash position.
Price Chart
Executive Summary
Belite Bio reported Q2 2026 financial results alongside the key catalyst that the FDA accepted its NDA with Priority Review for tinlarebant in Stargardt disease (PDUFA Feb 12, 2027). The pre-revenue clinical-stage biotech posted a wider net loss of $28.4M (vs $16.3M YoY) and a GAAP EPS of -$0.70 (vs -$0.50), driven by increased R&D and SG&A spending as it builds commercial infrastructure. The NDA acceptance and positive secondary qAF data from the DRAGON trial are the dominant drivers, making the financial deterioration secondary for a pre-commercial biotech with a clear regulatory catalyst ahead.
Key Facts
- FDA accepted NDA with Priority Review for tinlarebant in STGD1; PDUFA target action date of February 12, 2027.
- Phase 3 DRAGON trial met primary endpoint; additional qAF data showed tinlarebant-treated subjects had stable-to-slightly-decreased qAF (~2%) vs ~20% increase for placebo at month 25.
- Q2 2026 net loss of $28.4M ($0.70/share) vs $16.3M ($0.50/share) in Q2 2025.
- Cash and cash equivalents of $279.9M plus $500.1M in U.S. treasury bills/notes as of June 30, 2026.
- DRAGON II trial (STGD1) completed enrollment with 73 subjects; PHOENIX trial (GA) completed enrollment with 530 subjects.
- Company planning a Commercial Day in September 2026 to provide launch preparation update.
Financial Impact
Pre-revenue clinical-stage biotech; net loss widened to $28.4M in Q2 2026 from $16.3M in Q2 2025. Cash burn is accelerating as the company builds commercial infrastructure ahead of potential approval. Total cash and investments of ~$780M provide runway through and beyond the PDUFA date.
Risk Factors
- FDA non-approval or Complete Response Letter (CRL) on February 12, 2027, would be a severe negative catalyst.
- Commercial execution risk — first-ever STGD1 treatment requires building a new market from scratch.
- PHOENIX GA trial interim analysis could disappoint, removing the second indication's optionality.
- Net loss is widening rapidly as SG&A scales up ahead of revenue; cash burn rate is increasing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001104659-26-095218 |
| Document: tm2623018d1_6k.htm | 0001104659-26-095218 |
| Document: 0001104659-26-095218-index-headers.html | 0001104659-26-095218 |
| Document: 0001104659-26-095218-index.html | 0001104659-26-095218 |
| Document: 0001104659-26-095218.txt | 0001104659-26-095218 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | 6-K | $147.34 | awaiting T+20 | — | $147.33 (−0.01%) |
Sep 9, 2026 6w ago | Insider Cluster | $175.07 $152.52 | ▲ +12.88% | ▲ +15.01% | $147.33 (+15.85%) |
Aug 12, 2026 10w ago | 6-K | $166.28 $173.79 | ▲ +4.52% | ▲ +6.26% | $147.33 (−11.40%) |
Aug 12, 2026 10w ago | Press Release | $166.28 $173.79 | ▲ +4.52% | ▲ +6.26% | $147.33 (−11.40%) |
Jun 12, 2026 19w ago | 6-K | $144.24 $147.03 | ▲ +1.93% | ▲ +2.68% | $147.33 (+2.14%) |
May 20, 2026 22w ago | Press Release | $143.36 $146.12 | ▲ +1.93% | ▲ +1.18% | $147.33 (+2.77%) |
Apr 21, 2026 26w ago | 6-K | $167.42 $139.70 | ▼ −16.56% | ▼ −19.72% | $147.33 (−12.00%) |
Apr 21, 2026 26w ago | Press Release | $167.42 $139.70 | ▼ −16.56% | ▼ −19.72% | $147.33 (−12.00%) |
Apr 9, 2026 28w ago | Insider Cluster | $181.17 $156.21 | ▲ +13.78% | ▲ +21.34% | $147.33 (+18.68%) |
Apr 9, 2026 28w ago | Insider Cluster | $181.17 $156.21 | ▲ +13.78% | ▲ +21.34% | $147.33 (+18.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers